Biotest AG: Stock option programme fails to achieve required majority
Biotest AG / AGM/EGM
Corporate-announcement transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Biotest AG: Stock option programme fails to achieve required majority
from preferred shareholders
Dreieich/Frankfurt/Main, 11 May 2006. With 83.46% of shareholders present,
the Annual General Meeting of Biotest AG, Dreieich, today approved by a
large majority (94.64%) the creation of conditional capital amounting to €
0.98 million to secure subscription rights under a company stock option
programme. At the subsequent meeting of preferred shareholders, however,
with 30.53% of shareholders present, the agenda item failed to achieve the
required three-quarters majority. Consequently, it is not possible to
implement the Biotest Long-Term Incentive Plan as scheduled. The programme
would have enabled more than 50 executives to participate in Biotest AG as
preferred shareholders. Biotest intended to use the programme to create
additional performance incentives and enhance its appeal as an employer.
Following the rejection of the programme, a new scheme will be developed
shortly.
The other motions proposed by the management were adopted with very few
dissenting votes. These included approving the authorisation to buy back
own shares as well as their subsequent disposal or withdrawal. The dividend
was raised from € 0.11 per ordinary share and preferred share to € 0.12 and
€ 0.18 respectively. The distribution amount rose as a result by 77% to €
1.56 million.
About Biotest
Biotest AG, Dreieich, Germany is a company that researches and manufactures
pharmaceutical, biotherapeutic and diagnostic products and has specialised
in immunology and haematology. In its Pharmaceutical segment, Biotest
develops immunoglobulines, clotting factors and albumins based on human
blood plasma. These are used for diseases of the immune system or
haematopoietic system. In addition, Biotest also researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and blood cancer. The Diagnostic segment spans
reagents and serology and microbiology systems which are used, for example,
in blood transfusions. Biotest has around 1,100 employees worldwide and its
shares are listed in the Frankfurt Stock Exchange’s Prime Standard.
Biotest AG: Dr. Michael Ramroth, Tel: +49 (0)6103 801-338
Fax: +49 (0)6103 801-347, e-mail: michael.ramroth@biotest.de
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
German Securities Code Number, ISIN ordinary shares: 522720, DE0005227201
German Securities Code Number, ISIN preferred shares: 522723, DE0005227235
Listed: Prime Standard/Official market
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
DGAP 11.05.2006
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstr. 5
63303 Dreieich Deutschland
Phone: +49 - 6103 / 801 - 0
Fax: +49 - 6103 / 801 - 150
email: mail@biotest.de
WWW: www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
indices:
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
